Bio-Rad Laboratories Inc. (NYSE:BIO) hit a new 52-week high on Thursday . The company traded as high as $158.50 and last traded at $155.98, with a volume of 220,491 shares changing hands. The stock had previously closed at $145.77.

A number of equities research analysts recently weighed in on BIO shares. Jefferies Group reaffirmed a “buy” rating on shares of Bio-Rad Laboratories in a research report on Wednesday, June 8th. Zacks Investment Research upgraded shares of Bio-Rad Laboratories from a “sell” rating to a “hold” rating in a research report on Wednesday, July 6th.

The stock has a market capitalization of $4.58 billion and a PE ratio of 42.63. The company has a 50-day moving average of $143.92 and a 200-day moving average of $138.99.

Bio-Rad Laboratories (NYSE:BIO) last issued its quarterly earnings results on Wednesday, August 3rd. The company reported $0.61 earnings per share for the quarter, missing analysts’ consensus estimates of $1.13 by $0.52. During the same period in the previous year, the business posted $0.97 earnings per share. The business had revenue of $516.80 million for the quarter, compared to analysts’ expectations of $497.80 million. Bio-Rad Laboratories’s revenue for the quarter was up 2.1% on a year-over-year basis. On average, equities analysts forecast that Bio-Rad Laboratories Inc. will post $3.10 earnings per share for the current year.

A number of hedge funds recently modified their holdings of the stock. Bank of Montreal Can increased its stake in shares of Bio-Rad Laboratories by 13.1% in the fourth quarter. Bank of Montreal Can now owns 10,021 shares of the company’s stock worth $1,390,000 after buying an additional 1,163 shares during the period. Comerica Bank increased its stake in shares of Bio-Rad Laboratories by 0.3% in the fourth quarter. Comerica Bank now owns 15,009 shares of the company’s stock worth $1,959,000 after buying an additional 38 shares during the period. Principal Financial Group Inc. increased its stake in shares of Bio-Rad Laboratories by 3.5% in the fourth quarter. Principal Financial Group Inc. now owns 66,434 shares of the company’s stock worth $9,212,000 after buying an additional 2,238 shares during the period. Morgan Stanley increased its stake in shares of Bio-Rad Laboratories by 356.6% in the fourth quarter. Morgan Stanley now owns 71,554 shares of the company’s stock worth $9,921,000 after buying an additional 55,884 shares during the period. Finally, BlackRock Advisors LLC increased its stake in shares of Bio-Rad Laboratories by 4.7% in the fourth quarter. BlackRock Advisors LLC now owns 114,344 shares of the company’s stock worth $15,855,000 after buying an additional 5,085 shares during the period.

Bio-Rad Laboratories, Inc (Bio-Rad) is a manufacturer and distributor of life science research and clinical diagnostics products. The Company manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.